drugset / Trial / NCT00673868
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
RandomizedParallel-groupOpen-labelTreatment
Summary
This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Center (DUMC), by measuring levels of CMV DNA and virus specific T cell precursors at intervals post-infusion.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-08-06
- Completion
- 2008-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMV Specific Cytotoxic T Lymphocytes | Cell therapy | 200000 cells/kg | — |
| Subject | CMV Specific Cytotoxic T Lymphocytes | Cell therapy | 500000 cells/kg | — |